logo

Staphylococcus aureus

Background:

>Staphylococcus aureus
     1]  MSSA (methicillin susceptible strains)
     2]  MRSA (methicillin resistant Staph aureus)

Staphylococcus aureus:
  • (facultative anaerobic Gram-positive coccal bacterium;  catalase-positive)
  • -Usually found in normal skin flora, anterior nares of the nasal passages, and respiratory tract.
  • -Frequent contributor to skin and respiratory infections.
  • -Antibiotic-resistant forms represent a growing problem (MRSA).
  • -Most common staphylococcal species to cause Staph infections.
  • -Presence of S. aureus does not always indicate infection.
  • Source: http://en.wikipedia.org/wiki/Staphylococcus_aureus

top of page



Methicillin-resistant Staphylococcus aureus (MRSA):
  • MRSA: any strain of S. aureus that has developed, through the process of natural selection, resistance to beta-lactam antibiotics, which include the penicillins (methicillin, dicloxacillin, nafcillin, oxacillin, etc.) and the cephalosporins.  Note:  Not more intrinsically virulent than other strains of Staphylococcus aureus, just more difficult to treat.
  • MSSA:  strains that are still sensitive to standard antibiotics.
  • S. aureus most commonly colonizes the anterior nares (the nostrils). The rest of the respiratory tract, open wounds, intravenous catheters, and the urinary tract are also potential sites for infection.
  • MRSA is especially troublesome in hospitals, prisons and nursing homes, where patients with open wounds, invasive devices, and weakened immune systems are at greater risk of infection than the general public.
  • The initial presentation of MRSA is small red bumps that resemble pimples, spider bites, or boils; they may be accompanied by fever and, occasionally, rashes. Within a few days, the bumps become larger and more painful; they eventually open into deep, pus-filled boils.
  • Other abbreviations:  CA-MRSA:  community-associated MRSA.  HA-MRSA: hospital acquired.
  • People are very commonly colonized with CA-MRSA and are completely asymptomatic. The most common manifestations of CA-MRSA are simple skin infections, such as impetigo, boils, abscesses, folliculitis, and cellulitis.
  • Individuals at greatest risk:
    • People with weak immune systems (HIV/AIDS, lupus, or cancer sufferers; transplant recipients, severe asthmatics, etc.)
    • Diabetics
    • Intravenous drug users
    • Users of quinolone antibiotics
    • Young children and the elderly
    • College students living in dormitories
    • People staying or working in a health care facility for an extended period of time
    • People who spend time in confined spaces with other people, including occupants of homeless shelters and warming centers, prison inmates, military recruits in basic training, etc.
    • Veterinarians, livestock handlers, and pet owners.
  • Healthcare provider-to-patient transfer is common, especially when healthcare providers move from patient to patient without performing necessary hand-washing techniques between patients.
  • Restricting antibiotic use:   Glycopeptides, cephalosporins and in particular quinolones are associated with an increased risk of colonisation of MRSA. Reducing use of antibiotic classes that promote MRSA colonisation, especially fluoroquinolones, is recommended in current guidelines.
  • Source: http://en.wikipedia.org/wiki/Methicillin-resistant_Staphylococcus_aureus

 


top of page

Therapy:

Important considerations:  The choice of an agent should be based on local antimicrobial sensitivities, site of infection, cost, and comorbid conditions.   Generally, the most common agents/regimens are listed first.  Listed dosages may need to be adjusted for renal dysfunction.

Staphylococcus aureus Methicillin susceptible (MSSA):
  1. Dicloxacillin 500mg orally four times daily
  2. Clindamycin  600mg IV every 6 or 8 hours or 300mg orally tid or qid
  3. Bactrim DS (TMP-SMX)  po bid
  4. Cephalexin 500 mg po qid
  5. Nafcillin 1-2 grams IVPB q4-6 hours
  6. Cefazolin 1 to 2 g IV every eight hours
  7. Vancomycin 1 gram  ivpb q12h (patient-specific dosing required) 


Staphylococcus aureus Methicillin-resistant (MRSA):
  1. LOW-MIC, high susceptibility: clindamycin, Bactrim (TMP-SMX),  or doxycycline
  2. Vancomycin - (patient-specific regimen - trough goal 15-20 mcg/ml)
  3. Linezolid 600 mg orally or IV q12h
  4. Daptomycin 6 mg/kg IV once daily.    - NOT FOR PNEUMONIA
  5. Ceftaroline  600mg IV q12h
  6. Quinupristin-Dalfopristin 7.5 mg/kg IV q8h
  7. Telavancin 10 mg/kg IV every 24hours




Reference(s)



Infectious Disease Section References:

  1. Anand N, Kollef MH. The alphabet soup of pneumonia: CAP, HAP, HCAP, NHAP, and VAP. Semin Respir Crit Care Med. Feb 2009;30(1):3-9.
  2. Arnold FW, LaJoie AS, Brock GN, Peyrani P, Rello J, Menéndez R, et al. Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results. Arch Intern Med. Sep 14 2009;169(16):1515-24.
  3. Baden LR, Eisenstein BI.Impact of Antibiotic Resistance on the Treatment of Gram-negative Sepsis. Curr Infect Dis Rep. 2000 Oct;2(5):409-416.
  4. Bartlett JG et al. Community-acquired pneumonia in adults: guidelines for management. Guidelines from the Infectious Diseases Society of America. Clin Infect Dis. 1998;26:811-38.
  5. Bartlett JG: Empirical therapy of community-acquired pneumonia: macrolides are not ideal choices. Semin Respir Infect 1997 Dec; 12(4): 329-33
  6. Bartlett JG.1998 Pocket Book of Infectious Disease Therapy., Ninth Edition. Baltimore,MD: Williams&Wikins,1998.
  7. Bernstein JM: Treatment of community-acquired pneumonia--IDSA guidelines. Infectious Diseases Society of America. Chest 1999 Mar; 115(3 Suppl): 9S-13S
  8. Brown SM, Jones BE, Jephson AR, Dean NC. Validation of the Infectious Disease Society of America/American Thoracic Society 2007 guidelines for severe community-acquired pneumonia. Crit Care Med. Dec 2009;37(12):3010-6.
  9. CDC. Update to CDC's sexually transmitted diseases treatment guidelines, 2006. fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep. Apr 13 2007;56(14):332-6.
  10. CDC. Centers for Disease Control and Prevention. 2010 STD Treatment Guidelines. http://www.cdc.gov/std/treatment/2010/default.htm
    Accessed: 4-15-2012.
  11. Cunha BA. Antibiotic Essentials 8th.ed. Jones & Bartlett Learning, 2009.
  12. Ewig S et al. Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae. Am J Respir Crit Care Med. 1999;159:1835-42.
  13. Fang WF, Yang KY, Wu CL, Yu CJ, Chen CW, Tu CY, et al. Application and comparison of scoring indices to predict outcomes in patients with healthcare-associated pneumonia. Crit Care. Jan 19 2011;15(1):R32.
  14. File TM Jr. Community-acquired pneumonia: recent guidelines for therapy. J Respir Dis. 1999;20:534-41.
  15. Gilbert DN, Moellering Jr RC, Eliopoulos GM, et al ed. The Sanford Guide to Antimicrobial Therapy, 40th ed. Sperryville, VA: Antimicrobial Therapy; 2010.
  16. Gold HS, Moellering RC. Antimicrobial-drug resistance. N Engl J Med. 1996;335:1445-1453.
  17. Gonzales R, Sande M: What will it take to stop physicians from prescribing antibiotics in acute bronchitis? Lancet 1995 Mar 18; 345(8951): 665-6
  18. Hooton TM, Stamm WE. Diagnosis and treatment of uncomplicated urinary tract infection. Infect Dis Clin North Am 1997;11:551-581.
  19. Lacy CF, Armstrong LL, Goldman MP, Lance LL. Drug Information Handbook. 20th ed. Hudson, OH: Lexi-Comp, Inc; 2011.
  20. Lipsky BA, Berendt AR.Principles and practice of antibiotic therapy of diabetic foot infections. Diabetes Metab Res Rev. 2000 Sep-Oct;16 Suppl 1:S42-6.
  21. Mandell LA , Wunderink RG , Anzueto A , et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults . Clin Infect Dis . 2007;44(suppl 2):S27–S72.
  22. Mufson MA.Pneumococcal Pneumonia. Curr Infect Dis Rep. 1999 Apr;1(1):57-64.
  23. Nabel EG, Federman DD. Infectious Diseases: The Clinician's Guide to Diagnosis, Treatment, and Prevention. Jackson, WY: Teton Data Systems, 2010.
  24. Phua J, See KC, Chan YH, Widjaja LS, Aung NW, Ngerng WJ, et al. Validation and clinical implications of the IDSA/ATS minor criteria for severe community-acquired pneumonia. Thorax. Jul 2009;64(7):598-603.
  25. Pirracchio R, Mateo J, Raskine L, Rigon MR, Lukaszewicz AC, Mebazaa A, et al. Can bacteriological upper airway samples obtained at intensive care unit admission guide empiric antibiotherapy for ventilator-associated pneumonia?. Crit Care Med. Sep 2009;37(9):2559-63.
  26. Reese RE, Betts RF: A Practical Approach to Infectious Diseases. 4th ed. Boston: Little, Brown, and Company; 1996: 251
  27. Runyon B. Ascites and spontaneous bacterial peritonitis. In: Feldman M, Friedman LS, Sleisenger MH, eds. Sleisenger & Fordtran's Gastrointestinal and Liver Disease. Vol 2. 8th ed. Philadelphia, Pa: Saunders; 2006:1935-64.
  28. Rybak MJ, Lomaestro BM, Rotschafer JC, et al: Therapeutic monitoring of vancomycin in adults: summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2009; 29:1275-1279.
  29. Stefani SD, Cadore LP, Villaroel RU, Azevedo S, Machado AL. Antibiotic Selection in the Treatment of Febrile Neutropenia: Current Approach and New Directions.
    Braz J Infect Dis. 1998 Jun;2(3):109-117.
  30. Stamm WE, Hooton TM. Management of urinary tract infections in adults. N Engl J Med 1993;329:1328-1334.
  31. Tan J, et al. Expert Guide to Infectious Diseases 2nd ed. Philadelphia: ACP Press/American College of Physicians, 2008.
  32. van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet. Oct 31 2009;374(9700):1543-56.
  33. Wiggins KJ, Craig JC, Johnson DW, Strippoli GF. Treatment for peritoneal dialysis-associated peritonitis. Cochrane Database Syst Rev. Jan 23 2008;CD005284.
  34. Workowski KA, Berman S. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. Dec 17 2010;59:1-110.






Disclaimer

The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.   Read the disclaimer
more Career Center image description
Medical Calculators - A thru Z
Lab Values - A thru Z